### Roundtable methodology

Chair India: C K Mukopadhayay, JNU

Chair Europe: Pr Christian Boitard (France)

#### **European Experts**

C Boitard (FR)

J W Bjorkman (NL)

I Hutter (NL)

R Polly (UK)

H Przuntek (DE)

#### **Indian Experts**

G N Qazi, Jamia Hamdard

N K Mehra, AIIMS

A Dixit, JNU

V S Chauhan, ICGEB

S Sinha, AIIMS

R N K Bamezai, JNU

A Tyagi, UDSC

C K Mukopadhayay, JNU

S Goswami, JNU

S B Nagendrakumar, IIL

### **Plenary session**

#### FP7

definition of *Research Lines* of mutual benefits to EU and Third countries

### **Work Programmes**

Research Lines of mutual benefits selected through a Roundtable process are NOT be inserted as such in the Work Programme.

□ data to be considered to avoid duplication of research lines already covered in previous FP7 calls for proposals

□ data to be considered to avoid duplication

calls for Specific International Cooperation Actions targeting India funded in 2008-2010

Infectious agents [influenza, HIV/AIDS, malaria, Tuberculosis, trypanosomatidae] Neglected infectious diseases

Vaccine [leishmania, helminths, neglected bacterial infections, childhood bacterial diarrheas]

**Bioprospecting for drug leads** 

Reproductive health [strategy, interventions]

Health economics [Access to health/medecines, Integration of health survey and health systems response, Impact/cost-effectiveness of existing health programs, Monitoring of health policy implementation & performance in relation to developing countries]

### Roundtable methodology

New INDIGO coordination and promotion meetings New Delhi, October 2009

> Bioinformatics for health structural biology for health Biomarkers & diagnostic

### **RESEARCH LINE PROPOSALS: 15**

I. Hutter (NL)	Ageing, health, population and society
	Research in health: research methodology, qualitative research and participatory action research
	Reproductive health/maternal and child health and health systems research
A. Dixit (JNU)	Cancer research
A. Dixit (JNU)	Diabetes: development of new therapeutic approaches
C. Boitard (Fr) S Gosdami	From nutritonal environment to metabolic and cardiovascular diseases
	Cardiovascular biology
N Kumar	Foot and mouth disease
	Tuberculosis and paratuberculosis
CK Mukhopadhyay	Iron 1- and microbial infection in macrophages;2- non alcoolic fatty acid liver disease; 3- and neuro-glial damage
H Przuntek (NL)	Synergistic effects of complementary medecine
D Kumar	Health, traditional medecine, drug discovery
M Kapla, H Kanami	Metabolomics, protein interaction

### **RESEARCH LINE PROPOSALS**

I. Hutter (NL)	Ageing, health, population and society
A. Dixit (JNU) C. Boitard (Fr) S Gosdami CK Mukhopadhyay	Diabetes: development of new therapeutic approaches
	From nutritonal environment to metabolic and cardiovascular diseases
	Cardiovascular biology
	Iron 1- and microbial infection in macrophages;2- non alcoolic fatty acid liver disease; 3- and neuro-glial damage
D Kumar	Health, traditional medecine, drug discovery
BC Das	Stem cell biology
M Kapla, H Kanami	Metabolomics, protein interaction → platform
A. Dixit (JNU)	Cancer research → coming call
H Przuntek (NL)	Neurodegeneration: Synergistic effects of complementary medecine → coming call

#### HEALTHY AGEING IN EUROPE AND INDIA

RESEARCH LINE	Healthy ageing in Europe and in India
description of Research line	Population level: social, financial health care and consequences Health care family, instutitional and individual levels Allopathic and traditional medicine Meaning of ageing, of being ederly, being healthy differs for culture and generation
main actors in Europe and India	Netherlands; UK; Germany, IIPS Mumbai, AllMedical Sciences Dehli, JNU, Pune, Hyderabad
Existing/emerging cooperation	Groningen-IIPS Mumbai-PRC India, Pune, and Dharwad, Bochum and Hyderabad
why is it a common challenge?	Ageing population, life expectancy increase, social, financial and health care and consequences  Different types of health care
already covered	Specific International Cooperation Actions targeting India? No
common research needs?	Partly and complementary issues
objective(s)	Get insight into the processes of healthy ageing in two different societies
expected results?	Better care in the ageing population

STEM	CELL	SINI	RION	MEDE	CINE
OILIVI		VII C.		VILUL	CIIVL

OTEM CELES IN DICINEDECTIVE		
RESEARCH LINE	Stem cells in biomedecine	
description of Research line	Stem cell identification, growth and lineage specific differentiation.  Pleuripotent adult stem cells  Factors influencing stem cell transplantation  Profiling of stem cells; genetic programming.  Cancer and precancer stem cells	
main actors in Europe and India	India:AIIMS, New Delhi;ACBR, Delhi University;CMC, Vellore;NII, New Delhi;NCBS, Banglore;NCCS, Pune;IISc, Banglore;NBRC, Gurgaon	
Existing/emerging cooperation	Emerging: A number of research groups in India are working on various aspects of stem cell biology involving embryonic and adult stem cell- both basic studies as well as clinical trails in chronic diseases	
why is it a common challenge?	Aspect common to all areas of human health; Indian groups are engaged in research on both embryonic and adult stem cells; on-going clinical trials involving stem cells in India; India has recently started an Institute dedicated to Stem Cell Biology. National Ethical guidelines.	
already covered	Specific International Cooperation Actions targeting India? No	
common research needs?	Ultimate aim is to achieve maximum regeneration possible and eventual return to normal function	
objective(s)	To foster cooperation between both basic and clinical groups of India and EU.	
expected results?	Enhanced understanding of stem cell biology and translate this into therapeutic applications	

### SCIENTIFIC VALIDATION OF TRADITIONAL MEDECINES

RESEARCH LINE	Scientific validation of traditional medecines and systems
description of Research line	Objective proof of the traditional properties using molecular designs. Scientific basis of the traditional philosophies will be dealt.
main actors in Europe and India	<u>EU:</u> 1.Dr Antonio Morandi, Ayurvedic Point, Milano, Italy2.Prof. Przuntek, Dept of Neurology and Complementary, edicine, University of Bochum, Germany.3.Dr. Claudia witt, Department of CA.Medicine, Charite Hospital, Berlin, Germany 4.Dr Gyorgy Blashko, Department of Pharmacy and Pharmacology, University Debrecene, Hungary. <u>India:</u> 1. Dr D.Vijaya kumar, Indian Institute of Chemical Technology, CSIR, Hyderabad.
Existing/emerging cooperation	proposal in FP7: Ayurvedic Point in 2008, Bochum and NKTH, Hungary; Dept of Neurology and Complementary, Medicine, Bochum, NKTH, Hungary under NKTH, Hungary and -DST, India.
why is it a common challenge?	Healthcare systems should be established and validated before implementation. Best regulations should be possible along with proof of the basic science being implemented. When a healthcare system is implemented/proposed to be used in a new condition, for a new population, one needs to study, understand and validate before implementing it. The increasing use of traditional / herbal medicines in Europe and rest of the world emphasizes the need of scientific validation of these traditional systems of medicines.
already covered	Specific International Cooperation Actions targeting India? No
common research needs?	Scientific basis of traditional medicines for better use will be useful on both parts.
objective(s)	Scientific validation of traditional medicines, foods, therapies and metabolomics of the said systems.
expected results?	Scientific validation of traditional medicines, foods, therapies and metabolomics of the said systems.

### NUTRITION, METABOLIC AND CARDIOVASCULAR DISEASES

RESEARCH LINE	Nutrition: from inflammation to metabolic and cardiovascular diseases
description of Research line	diabetes metabolic and liver diseases macro and microvascular complications Integrated –omics, preclinical models, biomarkers therapeutic approaches
main actors in Europe and India	many
Existing/emerging cooperation	high potential
why is it a common challenge?	specificity of phenotypes makes them complementary
already covered	Specific International Cooperation Actions targeting India? No
common research needs?	high & increasing incidence, socioeconomic burden, interface between diverse genomes and environment
objective(s)	better understanding toward prevention
expected results?	mechanisms, high throughput phenotyping, biomarkers, prevention of complications, therapeutic targets, interaction between clinical departments and basic research labs.